
Sartorius Stedim Biotech, a leading international supplier for the
biopharmaceutical and biotech industries, has announced the expansion of its
standard range of Flexel® products by Flexel® for Magnetic Mixers.
This product series, which has so far covered a range of capacities from 50L to 1,000L, now offers new volumes of 1,500 L and 2,000 L, as well as proven scalable,
ready-to-use mixing technology to enhance process flexibility in
biomanufacturing and optimize manufacturing costs. This single-use magnetic
mixing system is designed for aseptic mixing in process development and manufacturing applications. It is ideal
for biopharmaceutical processes that require powerful mixing torque,
such as buffer preparation, media preparation, product resuspension and homogenization applications.
Flexel® for Magnetic Mixers is a non-invasive, mixing unit that
uses extensively qualified Sartorius Stedim
Biotech Flexel® 3D bag technology, the proven stainless steel Palletank® container and ATMI patented mixing
technology. A stainless steel cross mounted on a
pulley system enables the single-use bag to be unfolded for easy filling and optimal drainage. Mixing is based
on a bottom-mounted magnetically-driven
impeller capable of providing hightorque mixing in large liquid volumes. Powder transfer is facilitated by
the
4-inch powder addition port that provides for direct connection of
a 15 L or a 30 L powder transfer bag suspended from a powder bag holder. The interchangeable
magnetic mixer drive unit is mobile, cart-mounted and designed to interface
with any of the Palletanks®.
With this product range extension, Sartorius Stedim Biotech is
continuing expand its offering and expertise in single-use mixing technologies
and to deliver solutions for all unit operations to accommodate a fast-growing biopharmaceutical
market.
For further information
click here
Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge
equipment and services for the development, quality assurance and production
processes of the biopharmaceutical industry. Its integrated solutions covering
fermentation, cell cultivation, filtration, purification, fluid management and
lab technologies are supporting the biopharmaceutical industry around the world
to develop and produce drugs safely, timely and economically. Sartorius Stedim
Biotech focuses on single-use technologies and value-added services to meet the
rapidly changing technology requirements of the industry it serves. Strongly
rooted in the scientific community and closely allied with customers and
technology partners, the company is dedicated to its philosophy of .turning
science into solutions.
Headquartered in Aubagne, France, Sartorius Stedim Biotech is
listed on the Eurolist of
Euronext Paris. With its own manufacturing and R&D sites in
Europe, North America and Asia and a global network of sales companies,
Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and
R&D site is in Germany. The company employs nearly 2,600 people, and in
2010 earned sales revenue of 432.9 million euros.